Literature DB >> 22796417

Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects.

A Morales-Piga1, J Bachiller-Corral, M J Trujillo-Tiebas, A Villaverde-Hueso, M L Gamir-Gamir, V Alonso-Ferreira, M Vázquez-Díaz, M Posada de la Paz, C Ayuso-García.   

Abstract

We aimed to investigate the epidemiological determinants, clinical features, and genetic pattern of FOP in our country by evaluating the entire population of patients identified according to a combination of methods. To achieve this, 24 individuals were confirmed as FOP cases, 17 of whom were alive at the end of 2011 (point prevalence=0.36 × 10(-6)). The gender distribution (male/female ratio=13/11) and the concurrent range of ages (from 4 to 53 years; mean ± SD: 30.2 ± 13.8) are in agreement with similar reports. Twenty-one (87.5%) had characteristic congenital malformations of the big toe, and short thumbs were found in 65.2% of cases. In addition, other skeletal malformations such us fusion of the posterior elements of the cervical spine (89.0%), knee osteochondromas (71%), scoliosis (54.5%), and short and broad femoral neck (52.6%) were observed. All had developed mature ossicles of heterotopic bone in typical anatomic and temporal patterns, ranging in number from 1 to 17 (9.5 ± 3.9). Age at appearance of first ossifying lesion varied from 3 months to 15 years. Mean age at diagnosis was 7.3 ± 5.1 years and the average delay in reaching the correct diagnosis after the onset of heterotopic ossification was 2.7 years (range=0-12 years). Biopsy of the pre-osseous lesions was performed in 11 of 20 (55.0%), providing no useful information for the diagnosis of FOP. Seven of 18 (38.9%) reported some hearing loss, and 5 (27.8%) experienced diffuse thinning of the hair or were bald. No patient had relatives with a typical FOP clinical picture. Fourteen of the 16 cases which were genetically investigated displayed the single heterozygous mutation c.617G>A in exon 4 of the ACVR1 gene. One of the two patients who did not present with the canonical ACVR1 mutation showed a heterozygous mutation c.774G>C in exon 5 leading to the substitution of Arginine 258 with a serine. The other patient had a heterozygous c.774G>T substitution in exon 5 leading to the same amino acid change (p.Arg258Ser). These two patients had only nonspecific abnormalities of the great toe, lacked the typical anatomic and developmental pattern of heterotopic ossification, and shared a trend toward uncommon clinical features. These results provide new insight on the epidemiological and clinical traits of FOP, reinforcing the notion of its worldwide homogeneity. The molecular characterization of ACVR1 sequence variation will contribute to the understanding of the genetic profile of this devastating disease in different geographical areas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796417     DOI: 10.1016/j.bone.2012.07.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

2.  The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.

Authors:  Wei Zhang; Keqin Zhang; Lige Song; Jing Pang; Hongxing Ma; Eileen M Shore; Frederick S Kaplan; Peijun Wang
Journal:  Bone       Date:  2013-09-17       Impact factor: 4.398

3.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

Review 4.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 5.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

6.  Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Authors:  Frederick S Kaplan; Joyce A Kobori; Carmen Orellana; Inmaculada Calvo; Monica Rosello; Francisco Martinez; Berta Lopez; Meiqi Xu; Robert J Pignolo; Eileen M Shore; Jay C Groppe
Journal:  Am J Med Genet A       Date:  2015-06-11       Impact factor: 2.802

7.  Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Authors:  Bernard J Smilde; Clemens Stockklausner; Richard Keen; Andrew Whittaker; Alex N Bullock; Annette von Delft; Natasja M van Schoor; Paul B Yu; E Marelise W Eekhoff
Journal:  BMC Musculoskelet Disord       Date:  2022-06-01       Impact factor: 2.562

Review 8.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

9.  Clinical, evolution and therapeutical considerations upon a case of fibrodysplasia ossificans progressiva (FOP).

Authors:  O Rogoveanu; R Traistaru; C T Streba; Z Stoica; R Popescu
Journal:  J Med Life       Date:  2013-12-25

10.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.